*This report is informational only and not medical advice.* STABLEize for HealthStream is a specialized clinical decision support tool designed for neonatal healthcare professionals. It serves as a digital bedside companion to the S.T.A.B.L.E. Program, focusing on the critical post-resuscitation stabilization window. Its primary differentiator is the Cardiac Anomalies Library, featuring 22 MP4 animations of congenital heart disease. The app is a B2B tool gated behind HealthStream institutional logins.
The App DNA
What makes this app unique?
For Neonatal healthcare professionals, including nurses, physicians, and therapists, who require specialized stabilization care references.
What does it look like?
Key features
Comprehensive bedside reference for Sugar, Temperature, Airway, Blood pressure, Lab work, and Emotional support.
22 severe congenital heart disease anomalies featuring MP4 animations of blood flow and palliative procedures.
Tools for corrected gestational age, temperature conversion, catheter insertion depth, and weight conversion.
Includes neuroprotective hypothermia checklists, neurologic exams, and dopamine hydrochloride mixing instructions.
How much does it cost?
The app is strictly B2B; it is not a consumer-facing product but a professional tool provided to employees of organizations that have purchased the S.T.A.B.L.E. program.
Velocity
Maintenance developmentnew contentShow more...
Development is currently in a maintenance phase with no major feature updates released in the last 6 months. The most recent activity was a significant content update in April 2026, which aligned the app with the 7th edition S.T.A.B.L.E. Program modules. Prior to this, the Android platform received a version update in November 2025 without accompanying release notes. The cadence suggests a focus on periodic clinical content updates rather than continuous feature development.
Who built it?
The STABLE Program
2 apps tracked · Medical
STABLEize - The STABLE ProgramUser Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for STABLEize for HealthStream
How's the Medical market?
The rivals identified
By WebMD
A high-velocity clinical reference tool with 16 releases in the last 6 months, capturing the broad medical audience this app serves.
- Includes a comprehensive drug interaction checker and formulary—features missing from this app's stabilization-focused toolkit.
- Offers integrated medical news and CME (Continuing Medical Education) tracking, positioning it as a daily-use habit vs. this app's situational bedside use.
- Utilizes a free, ad-supported model for all clinicians, whereas this app requires a specific HealthStream enterprise login.
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for STABLEize for HealthStream
Where is it heading?
- v1.1.2 added 7th edition modules and PGE1 dosing (April 2026) — indicates active clinical maintenance.
- Android version has not been updated since Nov 2025 — creates a feature gap for non-iOS users.
The SWOT
- Proprietary MP4 cardiac animations for physiological clarity
- Direct alignment with the industry-standard S.T.A.B.L.E. Program
- Institutional lock-in via HealthStream integration
- Integration with hospital EHR systems (Epic/Cerner) for faster access
- Expansion of visual procedure guides to Airway and Lab modules
- Development of offline-first search capabilities
Next best moves
Synchronize Android version to v1.1.2
+ 2 more prioritized movesFeature gaps
Drug interaction checker and formulary (available in Medscape) +2
Bottom line
STABLEize is a high-authority niche tool whose value is anchored in its unique cardiac animations and S.T.A.B.L.E. Program branding. However, its utility is limited by the lack of a drug formulary and a lagging Android update cycle, which risks losing users to broader clinical references like Medscape.
Unlock 3 critical frictions, 3 market threats, 2 more prioritized moves and the analyst’s take.
Access the full report for freeReport last updated